This is the largest weight loss reported in any retatrutide Phase 3 trial to date and forms the basis of Lilly's obesity regulatory submission
In addition, all currently available GLP-1R therapies are peptide agonists, most of which require subcutaneous administration [140]
Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study
Aerobic fitness, resistance training, balance, coordination, and muscle preservation all matter
Delivery methods other than injections and oral pills, such as sublingual drops and dissolving tablets, have not been tested in clinical trials
I know it can be difficult to make that a priority regularly